Is the MDS-UPDRS a Good Screening Tool for Detecting Sleep Problems and Daytime Sleepiness in Parkinson’s Disease?
Table 1
Clinical characteristics of the study cohort.
Characteristics
Mean/number
Percentage
Age
65.6 ± 9.7
Disease-duration
8.3 ± 7.8
Education years
11.8 ± 3.2
Sex
293 males
63.7%
Fluctuation
236
51.3%
Dyskinesia
184
40.0%
Hoehn-Yahr stage I
31
6.7%
Hoehn-Yahr stage II
275
59.8%
Hoehn-Yahr stage III
115
25.0%
Hoehn-Yahr stage IV
28
6.1%
Hoehn-Yahr stage V
11
2.4%
Deep brain stimulation therapy
113
24.5%
Levodopa/carbidopa intestinal gel infusion therapy
10
2.2%
Levodopa
358
77.8%
Dopamine agonists
299
65.0%
Without medication
14
3.0%
Levodopa and dopamine agonist combination
118
25.7%
COMT-inhibition
208
45.2%
MAO-inhibition
108
23.5%
Anticholinergic therapy
10
2.2%
Presence of dementia
10
2.2%
Antipsychotic medication
8
1.74%
Sedative medication usage
25
5.43%
Presence of dementia was defined as having scores ≤125 points on Mattis Dementia Rating Scale and/or scores ≤22 points on Montreal Cognitive Assessment.
